Sosei Group Corporation (JP:4565)
:4565
Want to see JP:4565 full AI Analyst Report?
4565 Stock Chart & Stats
¥862.00
-¥10.00(-0.99%)
At close: 4:00 PM EST
¥862.00
-¥10.00(-0.99%)
Day’s Range― - ―
52-Week Range¥723.00 - ¥1,247.00
Previous CloseN/A
Volume458.60K
Average Volume (3M)945.56K
Market Cap
¥107.51B
Enterprise Value¥151.74B
Total Cash (Recent Filing)¥11.60B
Total Debt (Recent Filing)¥55.83B
Price to Earnings (P/E)11.0
Beta1.07
Next Earnings
Aug 07, 2026EPS Estimate
-3.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-110.53
Shares Outstanding91,733,130
10 Day Avg. Volume1,166,890
30 Day Avg. Volume945,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.9
Revenue Forecast (FY)¥38.16B
Bulls Say, Bears Say
Bulls Say
Commercial Product MomentumSosei's established commercial engine, led by PIVLAZ, generates durable product revenue and a high-share position in Japan. Market leadership reduces commercialization risk, supports predictable near-term product sales, and creates a platform for cross-selling and efficient launches (e.g., vamorolone).
Strong Margins And Revenue GrowthHealthy gross margins (~72%) and mid-teens revenue growth indicate structurally attractive unit economics for partnered and product sales. These margins provide resilience to fund R&D or absorb pricing pressure, improving the long-term ability to invest selectively in high-return programs.
Pipeline With Phase II‑ready Assets And Partner ProgramsHaving Phase II‑ready internal assets plus multiple partner‑led late‑stage programs creates durable optionality: out‑licensing, milestone potential, and subsequent royalties. A diversified pipeline raises the odds of value‑realizing BD events over a multi‑quarter horizon.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flows reflect ongoing cash burn and an inability to self‑fund the clinical and commercial agenda. This structural cash gap increases reliance on external financing, potentially diluting shareholders or raising leverage, and constrains reinvestment flexibility.
Declining Milestone Revenue & BD UncertaintyRevenue visibility is weakened by partner‑dependent milestone volatility. A decline in milestone receipts underscores that future income is contingent on third‑party progress and BD execution, making medium‑term forecasts and funding plans vulnerable to timing and deal‑outcome risk.
Platform R&D Pressure And Restructuring NeedsThe need to refocus the U.K. discovery platform, alongside higher R&D spend in FY2025, signals structural execution and capital allocation challenges. Restructuring can incur further one‑offs and delay productivity gains, while suboptimal platform returns raise long‑term efficiency concerns.
Sosei Group News
4565 FAQ
What was Sosei Group Corporation’s price range in the past 12 months?
Sosei Group Corporation lowest stock price was ¥723.00 and its highest was ¥1247.00 in the past 12 months.
What is Sosei Group Corporation’s market cap?
Sosei Group Corporation’s market cap is ¥107.51B.
When is Sosei Group Corporation’s upcoming earnings report date?
Sosei Group Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 82 days.
How were Sosei Group Corporation’s earnings last quarter?
Sosei Group Corporation released its earnings results on May 01, 2026. The company reported ¥19.82 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.82.
Is Sosei Group Corporation overvalued?
According to Wall Street analysts Sosei Group Corporation’s price is currently Overvalued.
Does Sosei Group Corporation pay dividends?
Sosei Group Corporation pays a Notavailable dividend of ¥2.5 which represents an annual dividend yield of N/A. See more information on Sosei Group Corporation dividends here
What is Sosei Group Corporation’s EPS estimate?
Sosei Group Corporation’s EPS estimate is -3.53.
How many shares outstanding does Sosei Group Corporation have?
Sosei Group Corporation has 91,733,130 shares outstanding.
What happened to Sosei Group Corporation’s price movement after its last earnings report?
Sosei Group Corporation reported an EPS of ¥19.82 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.957%.
Which hedge fund is a major shareholder of Sosei Group Corporation?
Currently, no hedge funds are holding shares in JP:4565
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sosei Group Corporation
Sosei Group Corporation (4565) is a biopharmaceutical company based in Japan, specializing in the discovery and development of innovative medicines. The company focuses on drug development in the fields of neurology, respiratory diseases, and oncology, leveraging its expertise in drug design and development to create novel therapies. Sosei Group operates through various subsidiaries and has a strong pipeline of product candidates that target significant unmet medical needs.
4565 Company Deck
4565 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial execution in Japan/APAC and meaningful pipeline progress (Phase II–ready assets and partner-led late-stage programs) are clear positives, supported by rising product sales and a profitable commercial unit. However, FY2025 was marked by material operating losses, a notable decline in milestone revenue, higher R&D spend, and one-off charges. Management has announced restructuring, cost-reduction targets (>10%), and a plan to refocus the U.K. discovery portfolio, with expectations that benefits will appear in H2 FY2026. Given the balance between encouraging commercial/pipeline momentum and significant near-term financial and execution risks, the overall tone is cautious and transitional: opportunities exist but require successful execution of BD, cost actions, and regulatory steps to translate into the company’s stated FY2026 profitability goals.View all JP:4565 earnings summariesTechnical Analysis
Peptidream
―
SanBio Co
―
Oncolys BioPharma, Inc.
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---